{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:45:20Z","timestamp":1788295520363,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>At present, multiple myeloma (MM) is still an essentially incurable hematologic malignancy. Although BCMA-targeted therapies have achieved remarkable results, BCMA levels were found to be downregulated in patients with MM who relapsed after these treatments. Therefore, the search for other antigens specific to MM has become a priority. Independently of BCMA expression, G-protein-coupled receptor family C group 5 member D (GPRC5D) is mainly expressed in the plasma cells of MM patients, while it is expressed in a limited number of normal tissues. Combining MM-specific antigen GPRC5D and T-cell-mediated therapies would be a promising therapeutic strategy for MM. Recently, we constructed a new anti-GPRC5D \u00d7 anti-CD3 T-cell-engaging bispecific antibody (TCB), BR109, which was capable of binding to human GPRC5D and human CD3\u03b5. Moreover, BR109 was proven to have relatively good stability and antitumor activity. BR109 could specifically trigger T-cell-mediated cytotoxicity against many GPRC5D-positive MM cells in vitro. Meanwhile, antitumor activity was demonstrated in MM cell line xenograft mouse models with human immune cell reconstitution. These preclinical studies have formed a solid foundation for the evaluation of MM treatment efficacy in clinical trials.<\/jats:p>","DOI":"10.3390\/cancers15245774","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T13:18:21Z","timestamp":1702300701000},"page":"5774","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma"],"prefix":"10.3390","volume":"15","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"},{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qi","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-3735","authenticated-orcid":false,"given":"Shu-Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Bioray Biopharmaceutical Co., Ltd., Taizhou 318000, China"},{"name":"Hisun Biopharmaceutical Co., Ltd., Hangzhou 311404, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple Myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Medical Progress Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ray, U., and Orlowski, R.Z. (2023). Antibody\u2013Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040590"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMe2209692","article-title":"T-Cell Engagers\u2014Modern Immune-Based Therapies for Multiple Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","article-title":"The Emerging Therapeutic Landscape of Relapsed\/Refractory Multiple Myeloma","volume":"102","author":"Tanenbaum","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"JCO"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and Characterization of a Human Orphan Family C G-Protein Coupled Receptor GPRC5D","volume":"1518","author":"Jensen","year":"2001","journal-title":"Biochim. Et Biophys. Acta (BBA)-Gene Struct. Expr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D Is a Target for the Immunotherapy of Multiple Myeloma with Rationally Designed CAR T Cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gao, Y., Wang, X., Yan, H., Zeng, J., Ma, S., Niu, Y., Zhou, G., Jiang, Y., and Chen, Y. (2016). Comparative Transcriptome Analysis of Fetal Skin Reveals Key Genes Related to Hair Follicle Morphogenesis in Cashmere Goats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151118"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D Is a Promising Marker for Monitoring the Tumor Load and to Target Multiple Myeloma Cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"key":"ref_19","first-page":"1232","article-title":"A T-Cell\u2013Redirecting Bispecific G-Protein\u2013Coupled Receptor Class 5 Member D x CD3 Antibody to Treat Multiple Myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G Protein-Coupled Receptor 5D in the Bone Marrow Is Associated with Poor Prognosis in Patients with Multiple Myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","article-title":"GPRC5D as a Novel Immunotherapeutic Target in Multiple Myeloma","volume":"20","author":"Nath","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Mazza","year":"2022","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","article-title":"Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and\/or Refractory (R\/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.HS9.0000843944.17251.d4","article-title":"Phase I Open-Label Single Arm Study of GPRC5D CAR T-Cells (OriCAR-017) in Patients with Relapsed\/Refractory Multiple Myeloma (POLARIS)","volume":"6","author":"Huang","year":"2022","journal-title":"HemaSphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","article-title":"Preclinical Activity of LM-305 Targeting G-Protein-Coupled Receptor Class 5 Member D (GPRC5D) Antibody Drug Conjugate for the Treatment of Multiple Myeloma","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res."},{"key":"ref_28","first-page":"467","article-title":"Bispecific Antibodies for the Treatment of B-Cell Lymphoma: Promises, Unknowns, and Opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_29","first-page":"1474","article-title":"Development and Validation of a Cell-Based Report Bioassay for a Bispecific Antibody Targeting CD3 and GPRC5D","volume":"31","author":"Li","year":"2022","journal-title":"Chin. J. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An Efficient Route to Huinan Bispecific IgG","volume":"16","author":"Goddard","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1","volume":"75","author":"Hezareh","year":"2001","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","article-title":"Challenges and Developing Solutions for Increasing the Benefits of IL-2 Treatment in Tumor Therapy","volume":"10","author":"Skrombolas","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An Anti\u2013Glypican 3\/CD3 Bispecific T Cell\u2013Redirecting Antibody for Treatment of Solid Tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 Bispecific T-Cell\u2013Redirecting Antibody for the Treatment of Multiple Myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Swan, D., Murphy, P., Glavey, S., and Quinn, J. (2023). Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Cancers, 15.","DOI":"10.3390\/cancers15061819"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5774\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:54Z","timestamp":1760132154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245774"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245774","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]}}}